Having identified the oncogenic role of TTK, NEK2, and CDK1 in ovarian cancer, and to contribute to the ongoing program in the development of anti-cancer drugs against ovarian cancer, we synthesize NSC777201 a derivative of our previously developed anticancer small molecule [26], evaluated its drug-likeness and its efficacy against both primary and multidrug resistance ovarian cancer cell lines. This evidence concerns the gene CDK1 and ovarian carcinoma.